
EGFR/MAPK, Not PI3K, Drive Colorectal Therapy Resistance
In a groundbreaking study published in Nature Communications, researchers have unveiled critical insights into why certain colorectal cancers develop resistance to epidermal growth factor receptor (EGFR) targeted therapies. The team, led by Qu, Hamidi, …